Sex influence on cancer immunotherapy efficacy and safety in advanced non-small cell lung cancer (NSCLC): A Canadian institution real-world experience

被引：0
|
作者：
Cohen, Sara Frida
Cruiziat, Diane
Naimer, Jeremy
Cohen, Victor
Kasymjanova, Goulnar
Spatz, Alan
Agulnik, Jason Scott
机构：
[1] McGill Univ, Montreal, PQ, Canada
[2] McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Peter Brojde Lung Canc Ctr, Montreal, PQ, Canada
[3] McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20618
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real-World Data for Integration Strategy of Radiotherapy (RT) With Immunotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Wang, F.
    D'Rummo, K. A.
    Cao, Y.
    Huang, C. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E455 - E455
  • [32] Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients
    Lee, Po-Hsin
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Huang, Yen-Hsiang
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Chang, Gee-Chen
    ANTI-CANCER DRUGS, 2021, 32 (10) : 1099 - 1104
  • [33] Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Tsiara, Anna
    Liontos, Michalis
    Kaparelou, Maria
    Zakopoulou, Roubini
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [34] Impact of afatinib dosing on safety and efficacy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) in a real-world setting
    Halmos, Balazs
    Tan, Eng-Huat
    Soo, Ross
    Cadranel, Jacques
    Lee, Min Ki
    Foucher, Pascal
    Hsia, Te-Chun
    Hochmair, Maximilian
    Griesinger, Frank
    Hida, Toyoaki
    Kim, Edward
    Melosky, Barbara
    Maerten, Angela
    Carcereny, Enric
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 160 - 161
  • [35] CANADIAN REAL-WORLD EXPERIENCE WITH NIVOLUMAB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH SYSTEMIC ANTICANCER THERAPY
    Carroll, R.
    Bortolini, M.
    Calleja, A.
    Munro, R.
    Kong, S.
    Daumont, M. J.
    Penrod, J. R.
    Lacoin, L.
    Cheung, W. Y.
    VALUE IN HEALTH, 2022, 25 (01) : S23 - S23
  • [36] Real-world biomarker testing trends in metastatic non-small cell lung cancer (NSCLC).
    Clinton, Natasha
    Patel, Manish R.
    Ayars, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18728 - E18728
  • [37] Real-world treatment sequencing in advanced non-small cell lung cancer (aNSCLC).
    Radtchenko, Janna
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations
    Lei, Lei
    Wang, Wen-xian
    Yu, Zong-yang
    Liang, Xian-bin
    Pan, Wei-wei
    Chen, Hua-fei
    Wang, Li-ping
    Fang, Yong
    Wang, Min
    Xu, Chun-wei
    Fang, Mei-yu
    TRANSLATIONAL ONCOLOGY, 2020, 13 (02): : 329 - 335
  • [39] Safety of pembrolizumab in patients with non-small cell lung cancer: a real-world study
    Thakrar, D. B.
    Essang, B.
    Echlin, A.
    Murdock, C.
    Lind, M. J.
    LUNG CANCER, 2019, 127 : S40 - S41
  • [40] A Single Institution Experience with Immunotherapy as an Effective Therapy Approach of Advance Non-Small Cell Lung Cancer (NSCLC)
    Martinez Perez, Julia
    Sanchez, Inmaculada
    Falcon Gonzalez, Alejandro
    Alonso, Miriam
    Flor Oncala, Maria Jose
    Corral, Jesus
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1293 - S1294
12345